Lynch syndrome is an autosomal dominant disorder that predisposes carriers of DNA mismatch repair (MMR) gene mutations to early-onset cancer. Germline testing screens exons and splice sites for mutations, but does not examine introns or RNA transcripts for alterations. Pathogenic mutations have not been detected in ~30% of suspected Lynch syndrome cases with standard screening practices. We present a 38-year-old male with a clinicopathological and family history consistent with Lynch syndrome, including loss of MSH2 expression in his tumor. Germline testing revealed normal MSH2 coding sequence, splice sites and exon copy number, however, cDNA sequencing identified an aberrant MSH2 transcript lacking exons 2-6. An inversion PCR on germline DNA identified an ~18 kb unbalanced, paracentric inversion within MSH2, with breakpoints in a long terminal repeat in intron 1 and an Alu repeat in intron 6. The 3′ end of the inversion had a 1.2 kb deletion and an 8 bp insertion at the junction with intron 6. Screening of 55 additional Australian patients presenting with MSH2-deficient tumors who were negative in germline genetic tests for MSH2 mutations identified another inversion-positive patient. We propose an Alu-mediated recombination model to explain the origin of the inversion. Our study illustrates the potential value of cDNA screening to identify patients with cryptic MMR gene rearrangements, clarifies why standard testing may not detect some pathogenic alterations, and provides a genetic test for screening individuals with suspected Lynch syndrome that present with unexplained MSH2-deficient tumors.
Introduction
Lynch syndrome is an inherited cancer disorder characterized by deficient DNA mismatch repair (MMR). The autosomal dominant inheritance of a loss-of-function genetic mutation or epimutation in one of the MMR genes (MLH1, MSH2, PMS2 and MSH6) predisposes carriers to colorectal, endometrial and other cancer types. Somatic inactivation of the wild-type allele in mutation carriers results in the loss of MMR protein expression and tumors with microsatellite instability. Diagnostic laboratories have traditionally used Sanger sequencing to detect germline coding or splice site mutations, and multiplex ligation-dependent probe amplification (MLPA) to identify exon deletions or duplications. These approaches have failed to detect a germline mutation in up to 30% of people with a clinical suspicion of Lynch syndrome (1) .
MSH2 is one of the most commonly mutated genes in Lynch syndrome with a heterogeneous mutation spectrum that includes large deletions, non-synonymous and missense mutations, and insertions and deletions that result in frameshift mutations (2) . Epimutations caused by deletion of the 3′ polyadenylation signal of the distal EPCAM gene also account for a proportion of Lynch syndrome cases (3) . To date, only two inversions have been reported in the DNA MMR genes. A paracentric inversion involving MSH2 exons 1-7 has been identified in multiple Lynch syndrome families using a combination of Southern blotting, inversion PCR and long-range PCR. The 5′ breakpoint of the inversion was located ~10 Mb distal to MSH2 and the 3′ breakpoint was in intron 7 (4) (5) (6) . Genomic DNA and cDNA-based methods were used to identify the other inversion on chromosome 3p22.2. The inversion breakpoints were in MLH1 intron 15 and LRRFIP2 intron 3 and generated two fusion transcripts between MLH1 and LRRFIP2 (7) .
Alu repeats are a family of short interspersed nuclear elements (SINE) that constitute about 10% of the human genome. Unequal homologous recombination mediated by Alu repeats causes genomic rearrangements (8) , including a 3.5-kb deletion incorporating MLH1 exon 16 (9) , an exon 7 and exons 4-8 deletion in MSH2 (10) , and deletions encompassing the 3′ end of EPCAM and the 5′ end of MSH2 (11) . A large deletion of exons 2-6 has also been reported in MSH2 (12) and the possible breakpoint regions in introns 1 and 7 contain Alu repeats (13) . It has been proposed that the region between the MSH2 promoter and exon 9 is prone to such rearrangements because of the high density of Alu repeats (10, 14, 15) .
cDNA sequencing has been used to screen MMR genes for mutations in Lynch syndrome families (16, 17) . The advantages of this approach are that the entire coding region can generally be amplified as one or a minimal number of overlapping fragments, and it can detect skipped exons, which may be indicative of splice site or branch point mutations. cDNA sequencing, however, is indirect and results need to be validated at the DNA level, defective alleles may be weakly or not expressed, and it may be difficult to distinguish between defective and naturally occurring alternatively spliced transcripts (16) . Interestingly, an MSH2 exons 2-6 cDNA deletion without any identifiable genetic alterations was identified in two individuals in a cDNA-based screen of an Australian cohort of Lynch syndrome families (16) and a 68-year-old female with high microsatellite instability tumors from Scotland (17) .
In this study, we hypothesized that a MSH2 structural rearrangement involving Alu repeats explained MSH2-deficient, early-onset colorectal cancer in a patient with suspected Lynch syndrome who had tested negative for MSH2 germline mutations.
Materials and methods

Patient recruitment
The study was undertaken according to ethics protocol HREC/09/SVH/63. Samples were collected following written informed consent. A 38-year-old male proband that had loss of MSH2 and MSH6 in his tumor tissue, and was negative in an MSH2 germline mutation screen by MLPA and Sanger sequencing, and an EPCAM deletion screen was referred to this study from a family cancer clinic. Immunohistochemistry and germline genetic testing were performed at SydPath (St Vincent's hospital, Sydney). A further 55 patients were identified from a study recruiting from 15 family cancer clinics in Australia. These individuals fulfilled the following criteria: (i) Clinical suspicion of Lynch syndrome based on clinical/family history; (ii) Tumor from the proband had loss of MSH2 immunostaining; (iii) Germline mutation screen by Sanger sequencing and MLPA detected no pathogenic sequence mutation in MSH2; (iv) No constitutional methylation of MSH2; (v) Provided informed consent. Diagnostic pathology for the additional patient identified in the PCR screen was performed at ACT Pathology and the Hunter Area Pathology Service (HAPS) in Australia.
Nucleic acid extraction
DNA was isolated from peripheral blood mononuclear cells (PBMCs) and lymphoblastoid cell lines (LCLs) by standard phenol-chloroform extraction. DNA was extracted from saliva samples using the Oragene-DNA kit (Genotek, #OG-500). Total RNA was extracted from PBMCs and LCLs using the PureLink® RNA Mini Kit (Life Technologies, #12183018A).
Cell culture
PBMCs were isolated from fresh peripheral blood of the proband and B cells were immortalized in our laboratory in 2002 by Epstein-Barr Virus transformation as described previously (18) . Briefly, PBMCs from fresh blood were resuspended at 4.0 × 10 6 /ml in RPMI medium (Gibco, Life Technologies). An equal volume of Epstein-Barr Virus containing culture supernatant was added to the PBMCs and incubated for 2 h at 37°C. Cyclosporine was added to a final concentration of 1 µg/ml and the cell suspension was incubated at 37°C in 5% CO 2 for 3 weeks. Cell clumps were separated by gentle pipetting and transferred to a 75-cm 2 cell culture flask with fresh RPMI medium supplemented with 10% fetal bovine serum, 100 U penicillin, 100 µg/ml streptomycin and 2 mM glutamate (Life Technologies), and cultured for at least 1 week at 37°C in 5% CO 2 prior to DNA and RNA isolation. All assays were performed on LCLs that had been passaged for less than 2 months after initial transformation and all results obtained for LCLs were verified by PCR and sequencing in PBMCs from the same patient.
cDNA synthesis and PCR amplification
One µg of total RNA was treated with 1 U of DNaseI (Life Technologies, # 18068-015) to remove contaminating DNA. cDNA synthesis was performed with the SuperScript™III cDNA Synthesis Kit using random hexamers (Life Technologies, #18080-051). MSH2 cDNA was amplified from 40 ng of cDNA using MSH2 exon 1F and MSH2 exon 7R (Table 1) . PCRs were performed in 25 µl with 1× PCR buffer, 2 mM MgCl 2 , 200 µM of each dNTP, 0.3 µM of each primer and 1 U of Platinum® Taq DNA polymerase (Life Technologies, #10966-018). PCR cycling conditions were an initial denaturation at 95°C for 5 min, followed by 40 cycles of 95°C for 1 min, 58.4°C for 1 min, 72°C for 2 min and final extension at 72°C for 10 min. PCR products were visualised on 2% agarose gels.
Direct sequencing of PCR products
PCR products were gel-extracted and purified with 0.22 µM spin-X® centrifuge tube filters (Sigma, #CLS8160-24EA) (19) . Sequencing was performed with the Big Dye Terminator v3.1 cycle sequencing kit (Applied Bio systems, # 4337454) and an Applied Biosystems 3730 DNA analyzer. Sequencing primers are shown in Table 1 .
Inversion PCRs
All PCRs (with the exception of MSH2 exons 1-7 inversion) were performed in 30 µl with 100 ng of genomic DNA, 1× PCR buffer, 2 mM MgCl 2 , 200 µM of each dNTP, 0.3 µM of each primer and 0.5 U of Platinum® Taq DNA polymerase (Life Technologies, #10966-018). The MSH2 exons 1-7 inversion PCR was performed in 20 µl with 100 ng of genomic DNA, 1× PCR buffer, 2.5 mM MgCl 2 , 200 µM of each dNTP, 0.5 U of Platinum® Taq DNA polymerase and 0.5 µM of the previously published F3/R3 primers (4). The positive control for the MSH2 exons 1-7 PCR was 100 ng of genomic DNA spiked with a cloned PCR product from an inversion-positive patient. A control PCR that amplified a product the same size as the inversion PCRs was also performed on each sample. Products were visualised on 2% agarose gels. PCR cycling conditions and all primer sequences are shown in Table 1 .
Results
Patient presentation
A 38-year-old male proband presented with three tubular adenomas (one with severe epithelial dysplasia) in the proximal
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lymphoblastoid cell lines MMR mismatch repair MLPA multiplex ligation-dependent probe amplification NMD nonsense-mediated mRNA decay PBMC peripheral blood mononuclear cells colon, a squamous cell carcinoma on the cheek, a thyroid follicular adenoma and a multi-nodular goitre ( Figure 1A ). At age 44, three tubular adenomas, two tubulovillous adenomas (one was a recurrent polyp at anastomosis site from previous hemicolectomy) and multiple hyperplastic polyps were resected from his colon. He also presented with two sebaceous adenomas and a duodenal polyp at age 48 and 52, respectively. Since age 48, he developed sebaceomas on the face every 1-2 years.
Immunostaining of the recurrent tubulovillous adenoma showed it had lost expression of MSH2 and MSH6, but retained MLH1 staining (PMS2 was not tested).
The proband had a family history of early-onset colorectal cancer ( Figure 1A ). His father presented with colorectal cancer at age 38 and died at 40. His sister had three hyperplastic polyps at 43 and a partial thyroidectomy (not cancer). His mother was diagnosed with non-Hodgkin lymphoma and colorectal cancer at 65 and 72, respectively. The proband's paternal grandmother had breast and liver cancer and cancer of unknown primary and died at age 47. She also had a hysterectomy at an unknown age and for unknown reasons.
Absence of MSH2 exons 2-6 in cDNA despite a normal DNA sequence Germline genetic testing on peripheral blood DNA from the proband detected no sequence alterations in the entire coding region and splice sites of MLH1 and MSH2. In addition, MLPA showed normal copy number of all MLH1 and MSH2 exons. Thus, despite loss of MSH2 staining in his tumor, the proband had an apparently normal germline MSH2 sequence. The proband's children were unavailable for diagnostic testing.
The possibility of abnormal processing of MSH2 transcripts was next investigated. Using PCR primers positioned in MSH2 exons 1 and 7 we detected two products, one at the expected size of ~1.3 kb, and another at 460 bp in his blood and LCLs ( Figure 1B) . Sequencing revealed that the 1.3 kb product consisted of exons 1-7 (data not shown), whereas the 460 bp product lacked exons 2-6 ( Figure 1C and D) . The fusion of exons 1-7 creates a frame shift and a premature stop codon at the third nucleotide in exon 7 ( Figure 1D) . A third fragment of ~1 kb in his LCLs was an artefact heteroduplex molecule formed through the hybridization of the wild-type and mutant cDNA molecules ( Figure 1B ). Using the same PCR assay, we detected only a single 1.3 kb product in LCLs from a healthy donor suggesting transcripts lacking exons 2-6 were not splicing isoforms found in normal cells. In summary, despite having normal exon copy number and no coding mutations, the proband had an aberrant MSH2 transcript with an exons 2-6 deletion. Based on these collective results it was hypothesized that the aberrant MSH2 transcript was caused by an inversion involving a region of the MSH2 gene containing these exons.
A cryptic germ line paracentric inversion within MSH2
Intron 1 of MSH2 is repeat-rich, consisting of 73% repetitive elements that includes AluSz, AluY and AluSc repeats from the Alu family. Previous descriptions of deletion breakpoints in Alu repeats within MLH1 (9) and MSH2 (10) led us to test if an inversion breakpoint occurred in these repeats. A forward primer (F1 L ) was placed in intron 1 immediately 5′ of the Alu repeats and tested using an inverse PCR approach in combination with Figure 2A ). F1 L and R1-R5 were all unidirectional primers and a PCR product was only expected if an inversion was present. Using primers F1 L and R3, a specific 2.5 kb product was generated from LCL and peripheral blood DNA of the proband, whereas this PCR product was not detected using healthy control DNA ( Figure 2B ). Sequencing using internal primers identified a fusion between an LTR (family ERVL-MaLR) in intron 1 of MSH2 (hg19, chr2: 47 634 013) and an inverted AluY repeat in intron 6 of MSH2 (hg19, chr2: 47 653 051) ( Figures 2C and 3B) . Based on the sequence of the 5′ breakpoint, we next designed another pair of unidirectional primers (F2 and R6) to characterize the 3′ breakpoint of the inversion in the proband. Using these primers, the predicted size of the PCR product was ~2.5 kb but a fragment of only 1.2 kb (not detected using healthy control DNA) was observed in the proband ( Figure 2B ). Direct sequencing of the PCR product and comparison to the reference genome (hg19) revealed a 1238 bp deletion at the 3′ end of the inverted sequence that was positioned immediately 5′ of an 8 bp insertion (TGATAGTG) and a 22 bp deletion of intron 6 ( Figures 2C  and 3B ) (c.[212-1526C_212-288Cdel; 212-287T_1276-3831Ainv; 1276-3830C_1276-3808TdelinsTGATAGTG]).
Inverted repeats can mediate recombination events that result in chromosomal rearrangements (20) . We therefore investigated if there was an Alu repeat in MSH2 introns 1 or 2 that shared a high sequence identity with the inverted AluY repeat in intron 6 (hg19, chr2:47, 652, 974 -47, 653, 277) that could account for the inversion. An AluY repeat in intron 1 (hg19, chr2: 47, 632, 306 -47, 632, 584) shared 87% identity with the inverted AluY repeat in intron 6 that contained the breakpoint ( Figure 3A) .
We next referred to the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) variants database to see if rearrangements or deletions involving these repetitive elements have been reported previously. An unpublished inversion involving MSH2 exons 2-6 with unknown breakpoint co-ordinates (c.212-?_1076+?inv) has been reported. Twenty seven large pathogenic deletions (class 5) encompassing exons 1, 2, 6 or 7 (i.e. with possible breakpoints in introns 1 and 6) are listed in the InSiGHT database but it was not possible to determine if the breakpoints occurred in the same repeats because they were identified with MLPA or Southern blotting and were not characterized at the sequence level.
MSH2 inversion explains a subset of Lynch syndrome cases with wild-type MSH2 sequence
To provide a more robust assay for detection of this specific paracentric inversion, a PCR assay that amplified a shorter product (558 bp) at the 5′ breakpoint of the inversion was optimized ( Figure 2B ). Although the forward primer was positioned within a repeat, it aligned uniquely to the genome and produced a single •, stop codon.
PCR product in the proband with the inversion but not in a healthy control ( Figure 2B ). An additional inversion-positive individual (patient 1) was identified in a screen of 55 additional patients ( Figure 2D ). The sequence of the 5' and 3' deletion breakpoints was identical to the original proband (Supplementary Figure 1A and B, available at Carcinogenesis Online). None of these patients had the described previously 10 Mb inversion of MSH2 exon1-7 (Supplementary Figure 1C , available at Carcinogenesis Online).
The tumor of patient 1 had loss of immunohistochemical staining for MSH2 and MSH6 but retained MLH1 staining (PMS2 was not tested). He had a personal history of ulcerative colitis and was diagnosed with colorectal cancer at 43. He was diagnosed with sebaceomas at 53 and 55, and at age 58 was diagnosed with ureteric cancer. The family history of patient 1 is largely unknown but his father died in his mid-sixties from primary gastric cancer that metastasized to the esophagus. His two sisters, niece (age 40) and nephew (age 42) are unaffected by cancer. In summary, this specific inversion accounts for ~4% (2/56) of the unexplained Lynch syndrome cases tested in this study.
Discussion
In this study, we identified and characterized a novel unbalanced paracentric inversion within the MSH2 gene in a family with a history of early-onset colorectal cancer. We showed that the inversion resulted in an abnormally spliced transcript that lacked exons 2-6 and demonstrated that this specific inversion accounts for a subset of unexplained Lynch syndrome cases.
The inversion resulted in the use of the splice donor site at exon 1 and the acceptor site at exon 7. The spliced transcript lacked the DNA binding domain encoded in exons 2-6 (21, 22) and contained a premature stop codon. Collectively this indicates the inversion generates a non-functional product and is pathogenic. A spliced transcript lacking exons 2-6 in healthy individuals has been previously reported in whole peripheral blood lymphocytes and T cells, but nor B cells or LCLs (23) . It was proposed that the deliberate introduction of a premature termination codon in normal cells may be a mechanism to channel transcripts into a degradation pathway (24) . Genetic testing using the PCR assay designed in our study, would establish if the previously reported cDNA deletion in other suspected Lynch syndrome families (16, 17) is the result of natural splicing or this inversion.
Nonsense-mediated mRNA decay (NMD) is a mechanism that degrades mRNAs containing premature stop codons and is coupled to translation and is also linked to pre-mRNA splicing in mammals (25) . The mutant transcript is predicted to be degraded by the NMD pathway because the premature stop codon is positioned more than 55 nucleotides upstream to the terminal exon-exon junction (26, 27) . The transcript was detected in peripheral blood and LCLs that were not treated with an NMD inhibitor such as emetine (28, 29) , suggesting that it was not rapidly degraded by the NMD pathway. In this instance, the stability of the mutant transcript enabled detection by sequencing, and our study further demonstrates the potential value of cDNA sequencing for aiding in the identification of inversions. We acknowledge that other types of inversions may generate unstable transcripts that are rapidly degraded, or prevent transcription, and treatment of LCLs with and without an NMDinhibitor such as emetine is recommended. We propose that an RNA extraction performed in conjunction with a DNA extraction would be useful for the identification of rearrangements in some people with suspected Lynch syndrome.
Alu repeats comprise 33% of intronic repeats in MSH2, 20% in MLH1, 42% in MSH6 and 45% in PMS2 (30) . It is therefore plausible that more cases of Lynch syndrome without detectable coding sequence alterations in MMR genes may be explained by inversions resulting from recombination events. Further work is required to establish if the exons 2-6 inversion listed in the InSiGHT variants database is identical to the one identified in this study. If it is the same inversion, haplotyping of individuals in both families would establish if it is a founder mutation or of independent origin.
We propose that chromatin looping and pairing of the inverted AluY repeats in introns 1 and 6 resulted in a homologous recombination event that inverted the intervening sequence of the MSH2 gene ( Figure 3B and C) . We cannot provide a definitive explanation for the 1.2 kb deletion, 8 bp insertion and 22 bp deletion at the 3′ end of the junction with intron 6, but indels have previously been described at inversion breakpoints (31) . Our model has parallels with inversions in the factor VIII gene in hemophilia A. Approximately 45% of patients with severe haemophilia A have no coding or splice site mutations in factor VIII, but have aberrant cDNA transcripts. These patients harbor an inversion caused by homologous recombination between inverted sequences located in intron 22 and upstream of the factor VIII gene (32) .
Computer algorithms can identify intronic deletions and duplications and complex structural rearrangements such as translocations and inversions in high-throughput sequencing datasets (33) (34) (35) . A targeted enrichment and high-throughput sequencing approach (ColoSeq) has been validated as a costeffective method to screen for germline MMR gene mutations (36) and has identified a germline inversion of exon 10 in APC in a case of familial adenomatous polyposis (37) . The tendency of rearrangement breakpoints to occur in repetitive elements makes unique read alignment challenging, however bioinformatics approaches have been used to map reads over repetitive elements in introns (38) , and high-throughput sequencing that includes introns could identify other cryptic rearrangements in the MMR genes.
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Funding
Cancer Australia and Cancer Council NSW (RG 13-07).
